Medical Conference Schedule Sept. 2013 through March 2014

New Remission Data on MG Patients Compelling
Source: Mitchell Kapoor (09/05/2025)

Kyverna Therapeutics Inc.'s (KYTX:NASDAQ) KYV-101 cell therapy drives a 15-month and longer remission in three patients treated on a compassionate use basis, noted an H.C. Wainwright & Co. report.

read more >

Seeking Formulation of New Drug, Biopharma Co. Signs LOI
Source: Dr. Douglas Loe (09/05/2025)

Rakovina Therapeutics Inc. (RKV:TSX.V) is seeking a novel formulation or drug delivery modalities that could modify the pharmacokinetics of its anti-cancer drug kt3283 to be more tumor targeted, noted a Leede Financial Inc. report.

read more >

Healthcare Firm Targets Alzheimer's With Technology Breakthrough
Source: Streetwise Reports (09/05/2025)

Healthcare company Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) rebrands and unveils plan to open brain-specific PET scanning clinics in North America to meet rising demand for Alzheimer's diagnostics. Read more to learn how this shift positions the company at the center of a growing medical need.

read more >

Cell Therapy Firm Kyverna Advances U.S. Phase 3 MG Trial
Source: Streetwise Reports (09/03/2025)

Kyverna Therapeutics Inc. (KYTX:NASDAQ) unveiled the design of its U.S. registrational Phase 3 trial for KYV-101 in myasthenia gravis during a Key Opinion Leader event, following ≥ 15-month remission data in Germany. Read more to see what sets this trial apart.

read more >

Biopharma Firm Accelerates AI-Driven Cancer Drug Discovery in Canada
Source: Streetwise Reports (09/03/2025)

Rakovina Therapeutics Inc. (RKV:TSX.V) secured fresh funding, advanced preclinical PARP and ATR programs, and leveraged exclusive AI platforms to target DNA-repair pathways. Read more for insight into its expanding role in precision oncology.

read more >